What changed in Baxter International Inc.'s latest annual report
In the year ended 31 Dec 2025, Baxter International Inc.'s revenue rose 5.7% to USD 11.24bn, from USD 10.64bn; long-term debt fell 28.4% to USD 9.44bn, from USD 13.18bn; total liabilities fell 25.6% to USD 13.95bn, from USD 18.76bn.
Year ended 31 Dec 2025. Source: 10-K filed 12 Feb 2026, read it on SEC EDGAR.
USD 10.64bn to USD 11.24bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 10.64bn | 11.24bn | Up 5.7% |
| Net income | -649.00m | -957.00m | Not comparable |
| Total assets | 25.78bn | 20.05bn | Down 22.2% |
| Total liabilities | 18.76bn | 13.95bn | Down 25.6% |
| Long-term debt | 13.18bn | 9.44bn | Down 28.4% |
| Cash and cash equivalents | 1.76bn | 1.97bn | Up 11.5% |
| Shareholders' equity | 6.96bn | 6.13bn | Down 12% |
Questions people ask
Did Baxter International Inc.'s revenue grow last year?
Revenue grew 5.7%, from USD 10.64bn to USD 11.24bn in the year ended 31 Dec 2025.
Is Baxter International Inc. profitable?
Not in its latest year: it reported a net loss of USD 957.00m in the year ended 31 Dec 2025. The year before: a net loss of USD 649.00m.
How much cash and debt does Baxter International Inc. have?
At its latest year end (31 Dec 2025), Baxter International Inc. reported cash and cash equivalents of USD 1.97bn and long-term debt of USD 9.44bn.
Where do these numbers come from?
From Baxter International Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Baxter International Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%